164 related articles for article (PubMed ID: 2277141)
1. Effects of cyclosporine on immunologic mechanisms in psoriasis.
Cooper KD; Voorhees JJ; Fisher GJ; Chan LS; Gupta AK; Baadsgaard O
J Am Acad Dermatol; 1990 Dec; 23(6 Pt 2):1318-26; discussion 1326-8. PubMed ID: 2277141
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis.
Cooper KD; Baadsgaard O; Ellis CN; Duell E; Voorhees JJ
J Invest Dermatol; 1990 May; 94(5):649-56. PubMed ID: 2324521
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis.
Horrocks C; Duncan JI; Sewell HF; Ormerod AD; Thomson AW
J Autoimmun; 1990 Oct; 3(5):559-70. PubMed ID: 2252524
[TBL] [Abstract][Full Text] [Related]
4. Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A.
Gupta AK; Baadsgaard O; Ellis CN; Voorhees JJ; Cooper KD
Arch Dermatol Res; 1989; 281(4):219-26. PubMed ID: 2673064
[TBL] [Abstract][Full Text] [Related]
5. T-lymphocyte-activating properties of epidermal antigen-presenting cells from normal and psoriatic skin: evidence that psoriatic epidermal antigen-presenting cells resemble cultured normal Langerhans cells.
Demidem A; Taylor JR; Grammer SF; Streilein JW
J Invest Dermatol; 1991 Sep; 97(3):454-60. PubMed ID: 1875046
[TBL] [Abstract][Full Text] [Related]
6. Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study.
Ho VC; Griffiths CE; Ellis CN; Gupta AK; McCuaig CC; Nickoloff BJ; Cooper KD; Hamilton TA; Voorhees JJ
J Am Acad Dermatol; 1990 Jan; 22(1):94-100. PubMed ID: 2298969
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.
Finzi AF; Mozzanica N; Cattaneo A; Chiappino G; Pigatto PD
J Am Acad Dermatol; 1989 Jul; 21(1):91-7. PubMed ID: 2787338
[TBL] [Abstract][Full Text] [Related]
8. Immunologic mechanisms in psoriasis.
Gottlieb AB
J Am Acad Dermatol; 1988 Jun; 18(6):1376-80. PubMed ID: 3290292
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine in psoriasis treatment. Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways.
Khandke L; Krane JF; Ashinoff R; Staiano-Coico L; Granelli-Piperno A; Luster AD; Carter DM; Krueger JG; Gottlieb AB
Arch Dermatol; 1991 Aug; 127(8):1172-9. PubMed ID: 1677800
[TBL] [Abstract][Full Text] [Related]
10. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy.
Vallat VP; Gilleaudeau P; Battat L; Wolfe J; Nabeya R; Heftler N; Hodak E; Gottlieb AB; Krueger JG
J Exp Med; 1994 Jul; 180(1):283-96. PubMed ID: 7516410
[TBL] [Abstract][Full Text] [Related]
11. The effect of cyclosporine on epidermal cells. I. Cyclosporine inhibits accessory cell functions of epidermal Langerhans cells in vitro.
Furue M; Katz SI
J Immunol; 1988 Jun; 140(12):4139-43. PubMed ID: 3259608
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis. Leukocytes and cytokines.
Cooper KD
Dermatol Clin; 1990 Oct; 8(4):737-45. PubMed ID: 2249364
[TBL] [Abstract][Full Text] [Related]
13. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation.
Gottlieb AB; Grossman RM; Khandke L; Carter DM; Sehgal PB; Fu SM; Granelli-Piperno A; Rivas M; Barazani L; Krueger JG
J Invest Dermatol; 1992 Mar; 98(3):302-9. PubMed ID: 1372027
[TBL] [Abstract][Full Text] [Related]
14. Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells.
Baadsgaard O; Gupta AK; Taylor RS; Ellis CN; Voorhees JJ; Cooper KD
J Invest Dermatol; 1989 Feb; 92(2):190-5. PubMed ID: 2645367
[TBL] [Abstract][Full Text] [Related]
15. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study.
Gottlieb SL; Heftler NS; Gilleaudeau P; Johnson R; Vallat VP; Wolfe J; Gottlieb AB; Krueger JG
J Am Acad Dermatol; 1995 Oct; 33(4):637-45. PubMed ID: 7545705
[TBL] [Abstract][Full Text] [Related]
16. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media.
Fisher GJ; Duell EA; Nickoloff BJ; Annesley TM; Kowalke JK; Ellis CN; Voorhees JJ
J Invest Dermatol; 1988 Aug; 91(2):142-6. PubMed ID: 2456356
[TBL] [Abstract][Full Text] [Related]
17. [Immunology in clinical practice. VII. Psoriasis].
Bos JD; de Rie MA
Ned Tijdschr Geneeskd; 1997 Nov; 141(48):2334-8. PubMed ID: 9550823
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.
Piskin G; Sylva-Steenland RM; Bos JD; Teunissen MB
J Immunol; 2006 Feb; 176(3):1908-15. PubMed ID: 16424222
[TBL] [Abstract][Full Text] [Related]
19. The effects of cyclosporine A on T lymphocyte and dendritic cell subpopulations in psoriasis.
Baker BS; Griffiths CE; Lambert S; Powles AV; Leonard JN; Valdimarsson H; Fry L
Transplant Proc; 1988 Jun; 20(3 Suppl 4):72-7. PubMed ID: 3260052
[No Abstract] [Full Text] [Related]
20. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.
Horroccks A; Ormerod AD; Duncan JI; Thomson AW
Clin Exp Immunol; 1989 Nov; 78(2):166-71. PubMed ID: 12412743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
